Wall Street Zen Upgrades Zenas BioPharma (NASDAQ:ZBIO) to Hold

Zenas BioPharma (NASDAQ:ZBIO) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

A number of other equities research analysts have also issued reports on ZBIO. Evercore began coverage on Zenas BioPharma in a research report on Wednesday, November 26th. They issued an “outperform” rating and a $55.00 price target for the company. Wedbush reaffirmed an “outperform” rating and issued a $45.00 price target on shares of Zenas BioPharma in a research report on Monday, December 22nd. Citigroup increased their price objective on Zenas BioPharma from $27.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, October 28th. Morgan Stanley downgraded shares of Zenas BioPharma from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $37.00 to $19.00 in a research note on Monday, January 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $43.14.

Zenas BioPharma Stock Down 4.2%

Shares of ZBIO stock opened at $25.88 on Friday. The stock has a 50 day moving average of $26.26 and a 200 day moving average of $26.09. The stock has a market cap of $1.39 billion, a P/E ratio of -3.66 and a beta of -1.47. Zenas BioPharma has a twelve month low of $6.11 and a twelve month high of $44.60. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.37.

Insider Buying and Selling

In other Zenas BioPharma news, Director Patricia L. Allen purchased 4,160 shares of Zenas BioPharma stock in a transaction that occurred on Friday, February 13th. The stock was purchased at an average price of $26.36 per share, with a total value of $109,657.60. Following the completion of the acquisition, the director owned 19,860 shares of the company’s stock, valued at approximately $523,509.60. This trade represents a 26.50% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Hongbo Lu acquired 25,985 shares of the firm’s stock in a transaction on Wednesday, February 11th. The stock was acquired at an average cost of $22.50 per share, with a total value of $584,662.50. Following the acquisition, the director owned 347,968 shares of the company’s stock, valued at $7,829,280. This trade represents a 8.07% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 202,845 shares of company stock valued at $3,747,185 in the last quarter. Company insiders own 16.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ZBIO. Quarry LP lifted its position in shares of Zenas BioPharma by 34.5% during the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after acquiring an additional 291 shares during the last quarter. Deutsche Bank AG increased its stake in Zenas BioPharma by 4.5% in the 4th quarter. Deutsche Bank AG now owns 12,781 shares of the company’s stock worth $464,000 after purchasing an additional 554 shares in the last quarter. CWM LLC raised its holdings in Zenas BioPharma by 48.3% during the 4th quarter. CWM LLC now owns 2,178 shares of the company’s stock worth $79,000 after buying an additional 709 shares during the period. Two Sigma Investments LP lifted its stake in Zenas BioPharma by 3.9% during the third quarter. Two Sigma Investments LP now owns 20,382 shares of the company’s stock valued at $452,000 after buying an additional 765 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Zenas BioPharma by 5.8% in the third quarter. Bank of America Corp DE now owns 14,809 shares of the company’s stock worth $329,000 after buying an additional 818 shares during the period.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.